Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia

• Status: Recruiting
• Trial end date: 2020-07-31
• Target enrollment: 0
• Participant gender: All

Summary

In the current situation it is of great importance to discover a safe, cost-effective and available treatment strategy in order to limit the rapidly spreading SARS-Cov-2. Recent studies have shown that hydroxychloroquine could have a role in the treatment of infected patients. It is however not very likely that hydroxychloroquine alone could be adequate for treatment of Covid-19 disease. Effective therapy that prevents the virus entrance should contain at least TMPRSS2 inhibitor or a competitive inhibitor of viral ACE 2 binding. The use of bromhexine at the dose adequate to selectively inhibit the TMPRSS2, resulting in preventing of viral entrance via TMPRSS2-specific pathway, coud be an effective treatment of Covid-19. In our study we would like to explore the therapeutic potential of bromhexin and hydroxychloroquine in Covid-19 patients.

Hypothesis

1. Combined treatment with bromhexin and hydroxychloroquine shortens the course of disease in hospitalized Covid-19 patients compared to hydroxychloroquine alone.

2. Combined treatment with bromhexin and hydroxychloroquine lowers the incidence of secundary pulmonary infections in hospitalized Covid-19 patients compared to hydroxychloroquine alone.

3. Combined treatment with bromhexin and hydroxychloroquine decreases the need for ICU admission in hospitalized Covid-19 patients compared to hydroxychloroquine alone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: General and Teaching Hospital Celje
• Treatments: Bromhexine; Hydroxychloroquine

Criteria

Inclusion Criteria:

• age > 18 years,

• confirmed infection (positive PCR from nasopharyngeal swab),

• fullfilled hospital admission criteria

Exclusion Criteria:

• pregnancy,

• known allergy for bromhexine or hydroxychloroquine,

• epilepsy,

• prolonged QTc interval,

• Child C liver disease,

• dementia,

• psychoorganic syndrome,

• terminal chronic disease